252M shares: ALNA Allena Pharmaceuticals NASDAQ close 24 Mar 2026, catalysts soon

Allena Pharmaceuticals, Inc. (ALNA) closed the NASDAQ session on 24 Mar 2026 at $0.075, making ALNA stock one of the most active small-cap biotech names today. Trading volume reached 252,311,606 shares after an intraday range of $0.06 to $0.1459. This activity followed no new public filings but rising investor attention to ALLN-346 clinical catalysts. We review the price action, core financial metrics, and a short-term forecast to put ALNA stock moves into perspective for U.S. investors.

ALNA stock price action and session summary

ALNA stock closed at $0.075 on NASDAQ in the United States in a market closed session. The stock opened at $0.0641, hit a day high of $0.1459, and a day low of $0.06. Volume spiked to 252,311,606, signaling heavy trading interest despite no fresh company release.

Key financials and valuation metrics for ALNA stock

Allena reports an EPS of -0.64 and a trailing PE of -0.12, reflecting ongoing development-stage losses. Cash per share is 0.92 and book value per share is 0.58, while current ratio stands at 2.11, supporting near-term liquidity. Market cap data is not meaningful in public feeds for this ticker, so investors should rely on balance-sheet metrics and cash runway.

Clinical program and news flow shaping ALNA stock

The lead program ALLN-346 (urate-degrading enzyme) remains the primary catalyst for ALNA stock. No major filings were released today, but media attention pushed volume. For industry commentary we note broader biotech coverage in major outlets source and we track company updates on the Allena site and our platform Meyka ALNA page.

Meyka AI rates ALNA with a score out of 100

Meyka AI rates ALNA with a score out of 100: 62.43 / Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, industry peers, financial growth, key metrics, forecasts, and analyst signals. These grades are model outputs for informational use only; they are not guaranteed and we are not financial advisors.

Technical and risk snapshot for ALNA stock

Short-term technicals show high volatility: a wide intraday range and heavy volume make ALNA stock prone to sharp swings. Key risks include development-stage cash burn and binary clinical outcomes. Strengths include a current ratio of 2.11 and cash per share 0.92, which help cover near-term operations.

Sector context: biotech trends affecting ALNA stock

ALNA operates in the Biotechnology industry within Healthcare. Sector sentiment and funding cycles materially alter ALNA stock moves. When small-cap biotech funding tightens, volatility rises; when clinical data or partnering news appears, small names often see outsized moves relative to peers.

Final Thoughts

Key takeaways: ALNA stock closed NASDAQ on 24 Mar 2026 at $0.075 with 252,311,606 shares traded, reflecting elevated investor interest ahead of potential clinical catalysts. Meyka AI’s forecast model projects a 12-month target of $0.16, implying an upside of 113.33% versus the current price of $0.075, and a 3-year target of $0.30 (implied upside 300.00%). Meyka AI’s forecast model projects these levels based on scenario-weighted clinical outcomes, sector comps, and balance-sheet trends. Remember, forecasts are model-based projections and not guarantees. Given the company’s negative EPS, trailing PE of -0.12, and biotech-specific binary risks, we rate ALNA as speculative and suitable only for risk-tolerant investors tracking clinical news and liquidity. For ongoing data and the latest ALNA news and analysis, check our platform and company filings

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.